Evidence map›Paper›PMID 26684009›Full record

Trial reportJournal of cardiovascular translational research2016

Everolimus-Eluting Bioresorbable Vascular Scaffold System in the Treatment of Cardiac Allograft Vasculopathy: the CART (Cardiac Allograft Reparative Therapy) Prospective Multicenter Pilot Study.

Michele Pighi, Fabrizio Tomai, Alessandro Petrolini, Leonardo de Luca, Giuseppe Tarantini, Alberto Barioli, Paola Colombo, Silvio Klugmann, Marco Ferlini, Maurizio Ferrario Ormezzano and 8 more

Abstract readClinical TrialMulticenter Study
PubMed Publisher
In one paragraph

Trial report in Journal of cardiovascular translational research, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.5field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 10 citations in OpenAlex.

  1. Safety and efficacy of everolimus-eluting bioresorbable vascular scaffold for cardiac allograft vasculopathy (CART).Clinical research in cardiology : official journal of the German Cardiac Society · 2024
    Article
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

18 authors at 9 institutions in 2 countries.

Michele PighiDepartment of Medicine, University of Verona, Piazzale Aristide Stefani n 1, 37126, Verona, Italy. michele.pighi@hotmail.it.
Fabrizio TomaiDepartment of Cardiovascular Sciences, European Hospital, Via Portuense, 700, 00149, Rome, Italy.
Alessandro PetroliniDepartment of Cardiovascular Sciences, European Hospital, Via Portuense, 700, 00149, Rome, Italy.
Leonardo de LucaDepartment of Cardiovascular Sciences, European Hospital, Via Portuense, 700, 00149, Rome, Italy.
Giuseppe TarantiniDepartment of Cardiac, Thoracic and Vascular Sciences, University of Padua Medical School, Padua, Italy.
Alberto BarioliDepartment of Cardiac, Thoracic and Vascular Sciences, University of Padua Medical School, Padua, Italy.
Paola ColomboDepartment of Cardiology and Cardiac Surgery, A. De Gasperis Niguarda Ca' Granda Hospital, Milan, Italy.
Silvio KlugmannDepartment of Cardiology and Cardiac Surgery, A. De Gasperis Niguarda Ca' Granda Hospital, Milan, Italy.
Marco FerliniDepartment of Cardiovascular Sciences, IRCCS Foundation, Policlinico San Matteo, Pavia, Italy.
Maurizio Ferrario OrmezzanoDepartment of Cardiovascular Sciences, IRCCS Foundation, Policlinico San Matteo, Pavia, Italy.
Bruno LoiDepartment of Cardiovascular Sciences, Brotzu Hospital, Cagliari, Italy.
Paolo CalabròCardio-thoracic and Respiratory Sciences Department, Second University of Naples, Monaldi Hospital, A.O.R.N. dei Colli, Naples, Italy.
Renato Maria BianchiCardio-thoracic and Respiratory Sciences Department, Second University of Naples, Monaldi Hospital, A.O.R.N. dei Colli, Naples, Italy.
Giuseppe FaggianDepartment of Cardiac Surgery, University of Verona, Piazzale Aristide Stefani n 1, 37126, Verona, Italy.
Alberto ForniDepartment of Cardiac Surgery, University of Verona, Piazzale Aristide Stefani n 1, 37126, Verona, Italy.
Corrado VassanelliDepartment of Medicine, University of Verona, Piazzale Aristide Stefani n 1, 37126, Verona, Italy.
Marco ValgimigliCardialysis, Rotterdam, The Netherlands.
Flavio RibichiniDepartment of Medicine, University of Verona, Piazzale Aristide Stefani n 1, 37126, Verona, Italy.
University of Verona · ITEuropean Hospital · ITAzienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda · ITOspedale Monaldi · ITUniversity of Padua · ITAzienda Ospedaliera G. Brotzu · ITCardialysis (Netherlands) · NLIstituti di Ricovero e Cura a Carattere Scientifico · ITPoliclinico San Matteo Fondazione · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cardiac allograft vasculopathy (CAV) is a form of accelerated atherosclerosis, which represents the leading cause of late morbidity and mortality after heart transplantation. The recent bioresorbable vascular scaffold (BVS) technology represents a potential novel therapeutic tool, in the context of CAV, by allowing transient scaffolding and concomitant vessel healing. Eligible subjects will be treated by using the Absorb Everolimus-Eluting BVS (Abbott Vascular, Santa Clara, CA, USA), and evaluated at pre-determined time points, up to 3 years since the index procedure. Both clinical and imaging data will be collected in dedicated case report forms (CRF). All imaging data will be analyzed in an independent core laboratory. The primary aim of the study is to evaluate the angiographic performance at 1 year of second-generation Absorb BVS, in heart transplant recipients affected by CAV.

Indexed as

Absorbable ImplantsCoated Materials, BiocompatibleAllograftsCardiac CatheterizationCardiovascular AgentsClinical ProtocolsCoronary Artery DiseaseEverolimusHeart TransplantationHumansItalyPilot ProjectsProspective StudiesProsthesis DesignResearch DesignTime FactorsCardiovascular AgentsCoated Materials, BiocompatibleEverolimusCardiac allograft vasculopathyEverolimus-eluting bioresorbable vascular scaffoldHeart transplant

Identifiers

PMID26684009
OpenAlexW2269749889

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.